E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease.
High-risk human papillomavirus (HPV) infections are the cause of nearly all cases of cervical cancer. Although the detection of HPV DNA has proved useful in cervical diagnosis, it does not necessarily predict disease presence or severity, and cannot conclusively identify the causative type when mult...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23226504/?tool=EBI |
| _version_ | 1819231241646374912 |
|---|---|
| author | Heather Griffin Zhonglin Wu Rebecca Marnane Vincent Dewar Anco Molijn Wim Quint Christine Van Hoof Frank Struyf Brigitte Colau David Jenkins John Doorbar |
| author_facet | Heather Griffin Zhonglin Wu Rebecca Marnane Vincent Dewar Anco Molijn Wim Quint Christine Van Hoof Frank Struyf Brigitte Colau David Jenkins John Doorbar |
| author_sort | Heather Griffin |
| collection | DOAJ |
| description | High-risk human papillomavirus (HPV) infections are the cause of nearly all cases of cervical cancer. Although the detection of HPV DNA has proved useful in cervical diagnosis, it does not necessarily predict disease presence or severity, and cannot conclusively identify the causative type when multiple HPVs are present. Such limitations may be addressed using complementary approaches such as cytology, laser capture microscopy, and/or the use of infection biomarkers. One such infection biomarker is the HPV E4 protein, which is expressed at high level in cells that are supporting (or have supported) viral genome amplification. Its distribution in lesions has suggested a role in disease staging. Here we have examined whether type-specific E4 antibodies may also allow the identification and/or confirmation of causal HPV-type. To do this, type-specific polyclonal and monoclonal antibodies against three E4 proteins (HPV-16, -18, and -58) were generated and validated by ELISA and western blotting, and by immunohistochemistry (IHC) staining of epithelial rafts containing these individual HPV types. Type-specific detection of HPV and its associated disease was subsequently examined using formalin-fixed paraffin-embedded cervical intra-epithelial neoplasias (CIN, (n = 247)) and normal controls (n = 28). All koilocytotic CIN1 lesions showed type-specific E4 expression of their respective HPV types. Differences were noted amongst E4 expression patterns in CIN3. HPV-18 E4 was not detected in any of the 6 HPV-18 DNA-positive CIN3 lesions examined, whereas in HPV-16 and -58 CIN3, 28/37 (76%) and 5/9 (55.6%) expressed E4 respectively, usually in regions of epithelial differentiation. Our results demonstrate that type-specific E4 antibodies can be used to help establish causality, as may be required when multiple HPV types are detected. The unique characteristics of the E4 biomarker suggest a role in diagnosis and patient management particularly when used in combination. |
| first_indexed | 2024-12-23T11:41:50Z |
| format | Article |
| id | doaj.art-1e1623690b7943f384e7754dffd52773 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-23T11:41:50Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-1e1623690b7943f384e7754dffd527732022-12-21T17:48:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01712e4997410.1371/journal.pone.0049974E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease.Heather GriffinZhonglin WuRebecca MarnaneVincent DewarAnco MolijnWim QuintChristine Van HoofFrank StruyfBrigitte ColauDavid JenkinsJohn DoorbarHigh-risk human papillomavirus (HPV) infections are the cause of nearly all cases of cervical cancer. Although the detection of HPV DNA has proved useful in cervical diagnosis, it does not necessarily predict disease presence or severity, and cannot conclusively identify the causative type when multiple HPVs are present. Such limitations may be addressed using complementary approaches such as cytology, laser capture microscopy, and/or the use of infection biomarkers. One such infection biomarker is the HPV E4 protein, which is expressed at high level in cells that are supporting (or have supported) viral genome amplification. Its distribution in lesions has suggested a role in disease staging. Here we have examined whether type-specific E4 antibodies may also allow the identification and/or confirmation of causal HPV-type. To do this, type-specific polyclonal and monoclonal antibodies against three E4 proteins (HPV-16, -18, and -58) were generated and validated by ELISA and western blotting, and by immunohistochemistry (IHC) staining of epithelial rafts containing these individual HPV types. Type-specific detection of HPV and its associated disease was subsequently examined using formalin-fixed paraffin-embedded cervical intra-epithelial neoplasias (CIN, (n = 247)) and normal controls (n = 28). All koilocytotic CIN1 lesions showed type-specific E4 expression of their respective HPV types. Differences were noted amongst E4 expression patterns in CIN3. HPV-18 E4 was not detected in any of the 6 HPV-18 DNA-positive CIN3 lesions examined, whereas in HPV-16 and -58 CIN3, 28/37 (76%) and 5/9 (55.6%) expressed E4 respectively, usually in regions of epithelial differentiation. Our results demonstrate that type-specific E4 antibodies can be used to help establish causality, as may be required when multiple HPV types are detected. The unique characteristics of the E4 biomarker suggest a role in diagnosis and patient management particularly when used in combination.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23226504/?tool=EBI |
| spellingShingle | Heather Griffin Zhonglin Wu Rebecca Marnane Vincent Dewar Anco Molijn Wim Quint Christine Van Hoof Frank Struyf Brigitte Colau David Jenkins John Doorbar E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease. PLoS ONE |
| title | E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease. |
| title_full | E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease. |
| title_fullStr | E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease. |
| title_full_unstemmed | E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease. |
| title_short | E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease. |
| title_sort | e4 antibodies facilitate detection and type assignment of active hpv infection in cervical disease |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23226504/?tool=EBI |
| work_keys_str_mv | AT heathergriffin e4antibodiesfacilitatedetectionandtypeassignmentofactivehpvinfectionincervicaldisease AT zhonglinwu e4antibodiesfacilitatedetectionandtypeassignmentofactivehpvinfectionincervicaldisease AT rebeccamarnane e4antibodiesfacilitatedetectionandtypeassignmentofactivehpvinfectionincervicaldisease AT vincentdewar e4antibodiesfacilitatedetectionandtypeassignmentofactivehpvinfectionincervicaldisease AT ancomolijn e4antibodiesfacilitatedetectionandtypeassignmentofactivehpvinfectionincervicaldisease AT wimquint e4antibodiesfacilitatedetectionandtypeassignmentofactivehpvinfectionincervicaldisease AT christinevanhoof e4antibodiesfacilitatedetectionandtypeassignmentofactivehpvinfectionincervicaldisease AT frankstruyf e4antibodiesfacilitatedetectionandtypeassignmentofactivehpvinfectionincervicaldisease AT brigittecolau e4antibodiesfacilitatedetectionandtypeassignmentofactivehpvinfectionincervicaldisease AT davidjenkins e4antibodiesfacilitatedetectionandtypeassignmentofactivehpvinfectionincervicaldisease AT johndoorbar e4antibodiesfacilitatedetectionandtypeassignmentofactivehpvinfectionincervicaldisease |